Article Details
Retrieved on: 2017-12-24 02:22:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>It has outperformed by 53.42% the S&P500. <b>Benchmark Capital</b> Advisors increased its stake in Sarepta Therapeutics I Com (SRPT) by 104% based on its latest 2017Q3 regulatory filing with the SEC. <b>Benchmark Capital</b> Advisors bought 10,400 shares as the company's stock rose 22.49% with the market.</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here